Flash FinanceUS
Market open S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · ARVINAS, INC. (ARVN)

Arvinas CMO Noah Berkowitz to Depart July 3, 2026; Separation Agreement Signed

Neutral Impact 3 of 5 leadership Written later

Arvinas said its chief medical officer, Noah Berkowitz, will leave the company effective July 3, 2026, and it has started a search for a replacement. Under a separation agreement signed June 22, 2026, he will receive nine months of base salary continuation, up to nine months of health premium support, and accelerated vesting of certain restricted stock units.

Key points

  • Chief medical officer Noah Berkowitz departs effective July 3, 2026, and will remain in the role until then.
  • Severance includes nine months of base salary continuation and up to nine months of health coverage premium payments.
  • Certain RSUs that would have vested on or before May 9, 2027 will vest early; other unvested RSUs will be forfeited.
  • The full separation agreement is expected to be filed with the Form 10-Q for the quarter ending June 30, 2026.

The filing

CompanyARVINAS, INC. (ARVN)
Form8-K, current report
Filed with the SECJun 22, 2026, 4:10 PM ET
Accession number0001628280-26-044627

Items reported: 5.02 Director / Officer Change

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:53 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on June 22, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.